SCHEMBL3379148

SCHEMBL3379148

COc1ccc(NS(C)(=O)=O)cc1-c1ccc(Cl)c(F)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 4/20 0.55
PTGS2 P35354 4/20 0.48
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
ALDH1A1 P00352 2/20 0.47
LMNA P02545 2/20 0.47
MAPT P10636 2/20 0.47
THRB P10828 2/20 0.47
HTT P42858 1/20 0.47
PKM P14618 1/20 0.47
TSHR P16473 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
BRD4 O60885 3/20 0.47
MAOA P21397 3/20 0.46
MAOB P27338 1/20 0.46
NR3C1 P04150 1/20 0.46
HPGD P15428 2/20 0.46
KDM4E B2RXH2 1/20 0.46
NPC1 O15118 1/20 0.46
HSD17B10 Q99714 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3376946 0.90 CYP17A1 (0.51) KDM1APTGS2MEN1KMT2AALDH1A1
SCHEMBL3377400 0.83 KIF11 (0.48) PTGS2NR3C1HPGDKITKIF11
SCHEMBL3376954 0.83 KIF11 (0.48) PTGS2NR3C1HPGDPTGS1KIT
SCHEMBL3377016 0.80 KIF11 (0.64) PTGS2ALDH1A1LMNAHTTHPGD
SCHEMBL3932771 0.79 KIF11 (0.50) MEN1KMT2AALDH1A1LMNAMAPT
SCHEMBL3375785 0.78 KIF11 (0.59) MAPTNR3C1KIF11CYP17A1
SCHEMBL3374747 0.75 KIF11 (0.51) PTGS2MEN1KMT2AALDH1A1LMNA
SCHEMBL3375676 0.72 KIF11 (0.52) KDM1ABRD4KIF11CYP17A1
SCHEMBL3378288 0.72 KIF11 (0.59) KDM1ABRD4NR3C1KIF11CYP17A1
SCHEMBL3375960 0.72 CYP17A1 (0.56) KDM1ANR3C1KITCYP17A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8389500-B2 Fused heterocyclic compounds as ion channel modulators GILEAD SCIENCES, INC. (US) 2013-03-05 US claimed
WO-2010056527-A2 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD PALO ALTO, INC. (US) 2010-05-20 WO claimed
US-20100113449-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD PALO ALTO, INC. (US) 2010-05-06 US claimed
US-8389500-B2 Fused heterocyclic compounds as ion channel modulators GILEAD SCIENCES, INC. (US) 2013-03-05 US disclosed
US-20100113449-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD PALO ALTO, INC. (US) 2010-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113449-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS KCNJ2, HCN4, KCNH2 KDM1A 2716/4885PTGS2 439/4885MEN1 1602/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.